Dr Smith said that PFL/BPL had elected to try dry heating of an existing product, 8CRV. In the proposal he recognised "our late start."
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Viral Inactivation
Key Person(s)
Dr James K Smith